{"preliminary_commentary":{"by_channel":{"x_thread":7},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"KRAS G12C","nct_id":"NCT04956640","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=kras-g12c-nct04956640. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"LY3537982 administered orally.","label":"LY3537982 (Dose Escalation)","type":"EXPERIMENTAL"},{"description":"LY3537982 administered orally either alone or with another investigational agent.","label":"LY3537982 (Dose Expansion)","type":"EXPERIMENTAL"},{"description":"LY3537982 administered orally either alone or with another investigational agent","label":"LY3537982 (Dose Optimization)","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2027-04","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small-Cell Lung","Colorectal Neoplasms","Endometrial Neoplasms","Ovarian Neoplasms","Pancreatic Neoplasms","Biliary Tract Neoplasms"],"enrollment":{"count":540,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"LY3537982","otherNames":["Olomorasib"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["KEYTRUDA®"],"type":"DRUG"},{"name":"Cetuximab","otherNames":["Erbitux"],"type":"DRUG"},{"name":"Pemetrexed","otherNames":["LY231514","Alimta"],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-05-29","lead_sponsor":"Eli Lilly and Company","official_title":"A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy","timeFrame":"Cycle 1 (21 Days)"},{"measure":"Phase 1b: To assess the safety and tolerability of LY3537982 when administered alone or in combination with other investigational agents","timeFrame":"Cycle 1 (21 Days)"},{"measure":"Phase 1b: To determine the optimal dose of LY3537982 to be administered to treatment-naïve participants with advanced NSCLC in combination with pembrolizumab","timeFrame":"Estimated up to 2 years"},{"measure":"To determine the optimal dose of LY3537982 to be administered to participants who have received at least one prior oxaliplatin- or irinotecan-containing regimen for advanced or metastatic CRC in combination with cetuximab","timeFrame":"Estimated up to 2 years"},{"measure":"To assess the antitumor activity of LY3537982 monotherapy in participants with advanced pancreatic cancer with KRAS G12C mutation","timeFrame":"Estimated up to 2 years"}],"references":[],"start_date":{"date":"2021-07-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","url":"https://clinicaltrials.gov/study/NCT04956640"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/kras-g12c-nct04956640"}